There are currently 73 active clinical trials seeking participants for Atrial Fibrillation research studies. The states with the highest number of trials for Atrial Fibrillation participants are Florida, California, Ontario and Texas.
Tulane iPredict, Prevent Study to Evaluate the Progression of Atrial Myopathy.
NCT04703166
Recruiting
To evaluate the progression of atrial myopathy through wearable devices and cardiac imaging.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
04/14/2025
Locations: Tulane University School of Medicine, New Orleans, Louisiana
Conditions: Atrial Fibrillation
Register for Updates
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
NCT05836987
Recruiting
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Gender:
ALL
Ages:
Between 22 years and 85 years
Trial Updated:
04/14/2025
Locations: Banner University, Phoenix, Arizona +83 locations
Conditions: Atrial Fibrillation
Register for Updates
320-detector Computed Tomography to Assess Myocardial Extracellular Volume Fraction in Patients With Atrial Fibrillation Before AF Ablation.
NCT06308094
Recruiting
This study explores the relationship between myocardial fibrosis and patient outcomes in Atrial Fibrillation (AF), specifically after catheter ablation. It aims to use Cardiac CT, an accessible tool, to measure left ventricular extracellular volume (ECV) as an indicator of fibrosis. The study will assess if higher ECV levels correlate with increased risks of AF recurrence, hospitalization, and poor cardiac function recovery. Positive findings could make ECV a key factor in deciding AF treatment... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/10/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Atrial Fibrillation
Register for Updates
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698
Recruiting
LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Affinity Hospital dba Grandview Medical Center, Birmingham, Alabama +49 locations
Conditions: Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Register for Updates
A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
NCT06455098
Recruiting
The purpose of this study is to demonstrate the safety and 12-month effectiveness of the BWI OMNYPULSE™ pulsed field ablation (PFA) platform for pulmonary vein isolation (PVI) in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF), an irregular heart rate that causes abnormal blood flow.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/29/2025
Locations: Phoenix Cardiovascular Research Group, Phoenix, Arizona +45 locations
Conditions: Atrial Fibrillation
Register for Updates
Ondansetron for the Management of Atrial Fibrillation
NCT05844501
Recruiting
"Afib" is a common irregular heartbeat. Afib can cause stroke, blood clots, dementia and death. Medicines used to treat Afib often do not work well and can cause serious side effects. Clinicians need medicines that work better for Afib. Medicines for Afib work by blocking a current in the heart called a potassium current. There is a newer potassium current called IKas that can contribute to Afib. A medicine called ondansetron is used to keep people with cancer from getting sick to their stomach... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/28/2025
Locations: Indiana Clinical Research Center, Indianapolis, Indiana +2 locations
Conditions: Atrial Fibrillation
Register for Updates
Tracking Results of Ablations to Combat AF Registry Generation 2
NCT05111015
Recruiting
The primary objective of the TRAC-AF Registry is to capture real-world safety and effectiveness data on AtriCure devices used to conduct concomitant open heart and/or hybrid ablation, and management of the Left Atrial Appendage concomitant to a cardiac ablation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Loma Linda University Medical Center, Loma Linda, California +10 locations
Conditions: Atrial Fibrillation
Register for Updates
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients with Esophageal Cancer
NCT06067438
Recruiting
This phase II trial studies how well amiodarone works in the prevention of atrial fibrillation (AF) after a minimally invasive esophagectomy (MIE) in patients with esophageal cancer. Atrial fibrillation (AF) is an irregular heart rhythm, usually associated with a rapid rate, that is caused by abnormal electrical activity within the atria. AF is the most common complication after MIE for esophageal cancer. There has never been a study of AF after MIE that has used unbiased assignment of patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Atrial Fibrillation, Esophageal Carcinoma
Register for Updates
Insertable Cardiac Monitor for Primary Atrial Fibrillation Detection in High-Risk Heart Failure Patients
NCT04818645
Recruiting
Patients with heart failure (HF) represent a large population of patients who are at high risk for complications related to undiagnosed atrial fibrillation (AF). However, currently there are limited modalities for early AF detection and subsequent stroke prevention in this high-risk population. An implantable cardiac monitor (ICM) is inserted subcutaneously and can provide long term arrhythmia information via remote monitoring. The ASSERT-AF study seeks to accurately define the burden of AF and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2025
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Atrial Fibrillation, Heart Failure
Register for Updates
WIBOFA - Validation of SCT02 With ECG-App for Detection of AF
NCT06351761
Recruiting
The aim of the study is to evaluate the performance of Withings SCT02 with embedded Withings ECG-app in the automatic detection of atrial fibrillation
Gender:
ALL
Ages:
22 years and above
Trial Updated:
02/27/2025
Locations: FWD Clinical Research, Boca Raton, Florida +3 locations
Conditions: Atrial Fibrillation
Register for Updates
Amplatzer Amulet LAAO Vs. NOAC
NCT04226547
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: University Hospital - Univ. of Alabama at Birmingham (UAB), Birmingham, Alabama +131 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: University of Alabama Hospital, Birmingham, Alabama +169 locations
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates